I’m running a quick poll to gauge the sequencing community’s opinion about Illumina’s proposed acquisition of PacBio. Just two simple questions. For the record, my answers are “yes” and “yes” (but I’m less confident about the second question). Check out my previous post to see my reasoning.
Should Illumina be allowed to acquire PacBio? (i.e., Would it be a net positive for the sequencing market?)
Will Illumina be allowed to acquire PacBio? (i.e., Will it pass anti-trust review?)